Project Grant R41AG085859
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$994K
Federal Agency
National Institute on Aging
Awardee
Transchromix LLC (F4MEAAM4J6F7)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27514, USA
Similar Awards
This $3,357,206 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel disease-modifying compound, BMS-984923, to treat Alzheimer's disease (AD). The grant recipient, Allyx Therapeutics Inc., will conduct clinical evaluation of BMS-984923 to evaluate its efficacy in restoring synapse density, hippocampal activity, and memory performance in preclinical AD models. The ultimate goal is to advance this small molecule...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $2,340,172 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop novel small molecule inhibitors targeting HDAC11 as potential therapeutics for Alzheimer's disease (AD). The 5-year grant, awarded on June 15, 2024, aims to explore structure-activity relationships of the lead HDAC11-selective inhibitor scaffold and...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of amyloid precursor protein (APP) as novel therapies for Alzheimer's disease (AD). The goal is to identify lead compounds that can effectively degrade APP, thereby reducing amyloid-beta (Aβ) production and accumulation, which plays a key role in AD pathogenesis. The project will involve...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a high-content screening pipeline to identify small molecule therapeutics that can reduce aberrant lipid accumulation in ApoE4-expressing oligodendrocytes, a key pathological feature of Alzheimer's disease. The $473,216 award, effective September 25, 2024 through August 31, 2025, will support two aims: (1) a targeted screen of ~2,500 lipid-modifying compounds and (2) an...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This federal Project Grant award, valued at $728,406.00 and administered by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), supports research to identify transcription factors that regulate the expression of the MAPT gene, which is associated with neurodegenerative diseases like Alzheimer's.
The key objectives are to: (1) use CRISPR screens to find transcription factors that can modulate MAPT transcription, (2) determine which trans-regulatory elements...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $500,000 Project Grant to Alzarrok Bio LLC for the development of a multi-target peptide drug for Alzheimer's disease (AD). The proposed peptide, named ALZ100, is derived from the human defense protein cathepsin G and is designed to inhibit four key mediators of AD pathogenesis: amyloid-beta (Aβ) oligomers and fibrils, the receptor for advanced glycation end-products (RAGE), the...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $201,250 Project Grant to Case Western Reserve University to study the role of m6A RNA methylation in amyloid-beta metabolism and Alzheimer's disease pathology. The research aims to determine how reduction in the m6A methyltransferase METTL3 contributes to increased amyloid-beta production and accumulation in Alzheimer's disease. Key objectives include investigating the effects of...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Neucyte Inc. a $500,000 Project Grant to develop an Alzheimer's disease (AD) and AD-related dementia (ADRD) microphysiological systems (MPS) platform using nanoluciferase-based technology. The goal is to create a scalable, reproducible "mini-brain" assembloid model using human induced pluripotent stem cells to facilitate high-throughput screening of potential AD/ADRD...
The National Institute on Aging (NIA) awarded Neuroindx, a for-profit woman-owned small business, a $514,862 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to develop an on-chip functional assay for identifying candidate microtubule-binding drugs to treat Alzheimer's Disease and Alzheimer's Disease Related Disorders (ADRDs). The award, with a period of performance from August 1, 2024 to July 31, 2025, will fund the creation of an in vitro platform that can...